Score Overview
Explore the 2021 public Archive ranking →
Where Anixa Biosciences Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ANIX
1998: 100.0% · 2021: 93.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-11-17 | $ 2.67 | — |
1 Year2025-11-17 | $ 4.20 | -36.43% |
5 Years2021-11-17 | $ 4.33 | -38.34% |
10 Years2016-11-17 | $ 5.05 | -47.13% |
20 Years2006-11-17 | $ 16.88 | -84.18% |
30 Years1996-11-15 | $ 165.63 | -98.39% |
| Period | Last Price2026-11-17 | 1 Year2025-11-17 | 5 Years2021-11-17 | 10 Years2016-11-17 | 20 Years2006-11-17 | 30 Years1996-11-15 |
|---|---|---|---|---|---|---|
| Price | $ 2.67 | $ 4.20 | $ 4.33 | $ 5.05 | $ 16.88 | $ 165.63 |
| Return | — | -36.43% | -38.34% | -47.13% | -84.18% | -98.39% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 0.00 | -$ 7M | $ 13M |
| 2025 | $ 0.00 | -$ 10M | $ 15M |
| 2024 | $ 0.00 | -$ 12M | $ 19M |
| 2023 | $ 210K | -$ 9M | $ 23M |
| 2022 | -$ 13M | $ 29M | |
| 2021 | $ 512K | -$ 12M | $ 35M |
| 2020 | $ 0.00 | -$ 10M | $ 9M |
| 2019 | $ 250K | -$ 11M | $ 5M |
| 2018 | $ 1M | -$ 13M | $ 5M |
| 2017 | $ 362.5K | -$ 5M | $ 6M |
| 2016 | $ 300K | -$ 5M | $ 3M |
| 2015 | $ 9M | -$ 1M | $ 6M |
| 2014 | $ 3M | -$ 9M | $ 5M |
| 2013 | $ 388.85K | -$ 10M | $ 898.17K |
| 2012 | $ 940.01K | -$ 4M | $ 839.69K |
| 2011 | $ 1M | -$ 7M | $ 3M |
| 2010 | $ 730.67K | -$ 5M | $ 1M |
| 2009 | $ 1M | -$ 16M | $ 2M |
| 2008 | $ 2M | -$ 5M | $ 1M |
| 2007 | $ 486.85K | -$ 5M | $ 1M |
| 2006 | $ 508.65K | -$ 7M | $ 1M |
| 2005 | $ 439.79K | -$ 4M | $ 506.52K |
| 2004 | $ 494.46K | -$ 3M | $ 1M |
| 2003 | $ 244.22K | -$ 3M | $ 1M |
| 2002 | $ 5M | -$ 3M | $ 854.82K |
| 2001 | $ 1M | -$ 3M | $ 1M |
| 2000 | $ 1M | -$ 4M | $ 1M |
| 1999 | $ 100K | -$ 8M | $ 2M |
| 1998 | $ 100K | -$ 7M | $ 5M |
| 1997 | $ 100K | -$ 5M | $ 12M |
| 1996 | $ 100K | -$ 5M | $ 22M |
| 1995 | $ 100K | -$ 3M | $ 8M |
| 1994 | $ 100K | -$ 3M | $ 6M |
| 1993 | $ 100K | -$ 2M | $ 8M |
| 1992 | $ 100K | -$ 1M | $ 4M |
| 1991 | $ 100K | -$ 1M | $ 4M |
| 1990 | $ 100K | -$ 1M | $ 2M |
| 1989 | $ 100K | -$ 1M | $ 2M |
| 1988 | $ 100K | -$ 1M | $ 1M |
| IPO1987 | $ 100K | -$ 1M | $ 700K |

Anixa Biosciences Inc fundamental performance
Between 2020 and 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 10M to -$ 10M. Revenue increased in 0 of those 5 years; net income in 3.
Between 2015 and 2025, revenue declined from $ 9M to $ 0.00 and net income went from -$ 1M to -$ 10M. Revenue increased in 4 of those 10 years; net income in 6.
Anixa Biosciences Inc currently holds a 20-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.
Membership
Continue ANIX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,187 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Lisata Therapeutics Inc.LSTA· revenue grew in 56% of years
Windtree Therapeutics IncWINT· revenue grew in 36% of years
Palatin Technologies, Inc. Common StockPTN· revenue grew in 47% of years
Kazia Therapeutics Ltd ADRKZIA· revenue grew in 31% of years
Trinity Biotech plcTRIB· revenue grew in 35% of years